FITC anti-human HLA-A,B,C Antibody

Pricing & Availability
Clone
W6/32 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class I, MHC class I
Isotype
Mouse IgG2a, κ
W632_FITC_072607
Human peripheral blood lymphocytes stained with W6/32 FITC
  • W632_FITC_072607
    Human peripheral blood lymphocytes stained with W6/32 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability
311403 25 tests $83.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
311404 100 tests $188.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8+ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Cat, Cow, Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.

Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Darrow TL, et al. 1989. J. Immunol. 142:3329.
  2. Stern P, et al. 1987. J. Immunol. 138:1088.
  3. Tran TM, et al. 2001. Immunogenetics 53:440.
  4. Barbatis C, et al. 1981. Gut 22:985.
  5. Ayyoub M, et al. 2004. Cancer Immunity 4:7.
  6. DeFelice M, et al. 1990. Cell. Immunol. 126:420.
  7. Fayen J, et al. 1998. Int. Immunol. 10:1347.
  8. Turco MC, et al. 1988. J. Immunol. 141:2275.
  9. Geppert TD, et al. 1989. J. Immunol. 142:3763.
  10. Wooden SL, et al. 2005. J. Immunol. 175:1383.
  11. Nagano M, et al. 2007. Blood 110:151.
  12. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed
  13. Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed
  14. Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed
  15. Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed
  16. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  17. Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79.
  18. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope)
  19. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  20. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  21. Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations
  1. Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  2. Mirlashari MR, et al. 2021. Transfusion. 61:1222. PubMed
  3. Weingarten-Gabbay S, et al. 2022. STAR Protoc. 3:101910. PubMed
  4. Di Matteo S, et al. 2022. Cancers (Basel). 15: . PubMed
  5. Yumoto K, et al. 2023. Transl Oncol. 31:101642. PubMed
  6. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
  7. Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed
  8. Robinson A, et al. 2017. Stem Cell Res Ther. 10.1186/s13287-017-0540-3. PubMed
  9. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  10. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
  11. Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed
  12. Abreu SC, et al. 2020. Am J Physiol Lung Cell Mol Physiol. 319:L908. PubMed
  13. Wu Y, et al. 2021. Nat Biomed Eng. 5:1336. PubMed
  14. McDaid WJ, et al. 2021. Nanoscale. 13:15010. PubMed
  15. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  16. Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed
  17. Tallerico R, et al. 2017. Oncoimmunology. 6:e1284718. PubMed
  18. Sharma R, et al. 2021. Nat Commun. 12:472. PubMed
  19. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
  20. Robinson A, et al. 2015. PLoS One. 10: 0139023. PubMed
  21. Yumoto K, et al. 2016. Sci Rep. 6:36520. PubMed
  22. OConnor RA, et al. 2021. OncoImmunology. 10(1):1940675. PubMed
  23. Liu X, et al. 2017. International Immunopharmacology. 10.1016/j.intimp.2017.04.012. PubMed
  24. Wei C, et al. 2012. J Allergy Clin Immunol. 129:1562. PubMed
  25. Meng J, et al. 2010. Clin Vaccine Immunol. 1.325694444. PubMed
  26. Chen X, et al. 2015. Mol Immunol. 65:34. PubMed
  27. Tangtanatakul P, et al. 2017. Sci Rep. 7:14517. PubMed
  28. Yin Z, et al. 2012. J Immunol. 189:2735. PubMed
  29. Takahashi A, et al. 2021. Front Oncol. 11:707473. PubMed
  30. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  31. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  32. Ng S, et al. 2022. Sci Rep. 12:14087. PubMed
  33. Chew GL et al. 2019. Dev Cell. 50(5):658-671 . PubMed
  34. Song L, et al. 2021. J Invest Dermatol. 141:903. PubMed
  35. Qi YA, et al. 2021. Mol Cell Proteomics. 20:100136. PubMed
  36. Mirlashari MR, et al. 2021. Proteomics Clin Appl. 15:e2100022. PubMed
  37. Tallerico R, et al. 2013. J Immunol. 190:2381. PubMed
  38. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
  39. Ritter C, et al. 2017. Scientific Reports. 10.1038/s41598-017-02608-0. PubMed
  40. Nosaka K, et al. 2021. Anticancer Res. 41:4741. PubMed
  41. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
RRID
AB_314872 (BioLegend Cat. No. 311403)
AB_314873 (BioLegend Cat. No. 311404)

Antigen Details

Structure
Ig superfamily
Distribution

All nucleated cells

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD8
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
3105 View all products for this Gene ID
UniProt
View information about HLA-A on UniProt.org
Go To Top Version: 2    Revision Date: 01/16/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account